×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
MRUS – merus n.v. - common shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
MRUS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/4
02:02 pm
mrus
Merus N.V. (MRUS): A Bull Case Theory [Yahoo! Finance]
Low
Report
Merus N.V. (MRUS): A Bull Case Theory [Yahoo! Finance]
11/17
07:10 am
mrus
Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab [Yahoo! Finance]
Low
Report
Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab [Yahoo! Finance]
10/31
10:07 am
mrus
Merus (NASDAQ:MRUS) had its "market perform" rating reaffirmed by analysts at BMO Capital Markets.
Low
Report
Merus (NASDAQ:MRUS) had its "market perform" rating reaffirmed by analysts at BMO Capital Markets.
10/25
12:09 pm
mrus
Merus (NASDAQ:MRUS) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Merus (NASDAQ:MRUS) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
10/24
10:00 am
mrus
Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety
Low
Report
Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety
10/23
12:43 pm
mrus
Merus Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS
Low
Report
Merus Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS
10/14
07:40 am
mrus
Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics [Yahoo! Finance]
Low
Report
Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics [Yahoo! Finance]
10/14
07:30 am
mrus
Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Low
Report
Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Date
Time
Symbol
Company Name
Action
%Chg
8/5/2025
04:07 pm
mrus
merus n.v. - common shares
MISS
Report
-2.8%
merus n.v. - common shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/28
04:30 pm
mrus
Form 4 Merus N.V. For: Nov 25 Filed by: Lundberg Sven Ante
Low
Report
Form 4 Merus N.V. For: Nov 25 Filed by: Lundberg Sven Ante
11/28
04:05 pm
mrus
Form 4 Merus N.V. For: Nov 25 Filed by: Shuman Harry
Low
Report
Form 4 Merus N.V. For: Nov 25 Filed by: Shuman Harry
11/14
04:40 pm
mrus
Form SCHEDULE 13G/A Merus N.V. Filed by: Paradigm Biocapital Advisors LP
Low
Report
Form SCHEDULE 13G/A Merus N.V. Filed by: Paradigm Biocapital Advisors LP
11/14
08:28 am
mrus
Form SCHEDULE 13G/A Merus N.V. Filed by: RTW INVESTMENTS, LP
Low
Report
Form SCHEDULE 13G/A Merus N.V. Filed by: RTW INVESTMENTS, LP
11/12
09:34 am
mrus
Form SCHEDULE 13G/A Merus N.V. Filed by: WELLINGTON MANAGEMENT GROUP LLP
Low
Report
Form SCHEDULE 13G/A Merus N.V. Filed by: WELLINGTON MANAGEMENT GROUP LLP
11/5
11:41 am
mrus
Form SCHEDULE 13G/A Merus N.V. Filed by: FMR LLC
Low
Report
Form SCHEDULE 13G/A Merus N.V. Filed by: FMR LLC
10/31
04:23 pm
mrus
Form PREM14A Merus N.V. For: Oct 31
Low
Report
Form PREM14A Merus N.V. For: Oct 31
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/12
Merus Announces Financial Results for the Fourth Quarter and Full Year 2019 and Provides Business Update
34.7%
10/25 Merus Announces Presentation and Poster on MCLA-128 and MCLA-129 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 16.3%
1/15 Form 4 Merus N.V. For: Jan 13 Filed by: BVF INC/IL 13.8%
9/19 Merus NV (NASDAQ: MRUS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 9.8%
4/3 Form 4 Merus N.V. For: Apr 01 Filed by: Throsby Mark 9.8%
11/4 Form 6-K Merus N.V. For: Nov 04 7.0%
4/24 Form SC 13G/A Merus N.V. Filed by: EcoR1 Capital, LLC 6.8%
3/19 Merus NV (NASDAQ: MRUS) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 6.3%
8/10 Merus NV (NASDAQ: MRUS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.9%
4/16 Form 8-K Merus N.V. For: Apr 15 5.8%
10/25 Merus Announces Presentation and Poster on MCLA-128 and MCLA-129 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 16.3%
1/15 Form 4 Merus N.V. For: Jan 13 Filed by: BVF INC/IL 13.8%
9/19 Merus NV (NASDAQ: MRUS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 9.8%
4/3 Form 4 Merus N.V. For: Apr 01 Filed by: Throsby Mark 9.8%
11/4 Form 6-K Merus N.V. For: Nov 04 7.0%
4/24 Form SC 13G/A Merus N.V. Filed by: EcoR1 Capital, LLC 6.8%
3/19 Merus NV (NASDAQ: MRUS) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 6.3%
8/10 Merus NV (NASDAQ: MRUS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.9%
4/16 Form 8-K Merus N.V. For: Apr 15 5.8%
TOP News Decliners
10/27
Merus Bispecific Antibody MCLA-128 Shows Encouraging Early Clinical Activity in Patients with Cancers Harboring NRG1 Gene Fusions
-16.2%
3/18 Merus NV (NASDAQ: MRUS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $14.00 price target on the stock. -10.8%
3/10 Form 4 Merus N.V. For: Mar 04 Filed by: Throsby Mark -8.1%
4/29 Form 10-K/A Merus N.V. For: Dec 31 -7.5%
8/19 Form 6-K Merus N.V. For: Jun 30 -6.9%
4/30 Form POS AM Merus N.V. -6.6%
3/7 Merus NV (NASDAQ: MRUS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $20.00 price target on the stock. -6.2%
5/20 Merus to Present at the RBC Capital Markets 2019 Healthcare Conference -5.9%
10/23 Merus NV (NASDAQ: MRUS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.3%
4/6 Form 4 Merus N.V. For: Apr 02 Filed by: Throsby Mark -4.6%
3/18 Merus NV (NASDAQ: MRUS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $14.00 price target on the stock. -10.8%
3/10 Form 4 Merus N.V. For: Mar 04 Filed by: Throsby Mark -8.1%
4/29 Form 10-K/A Merus N.V. For: Dec 31 -7.5%
8/19 Form 6-K Merus N.V. For: Jun 30 -6.9%
4/30 Form POS AM Merus N.V. -6.6%
3/7 Merus NV (NASDAQ: MRUS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $20.00 price target on the stock. -6.2%
5/20 Merus to Present at the RBC Capital Markets 2019 Healthcare Conference -5.9%
10/23 Merus NV (NASDAQ: MRUS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.3%
4/6 Form 4 Merus N.V. For: Apr 02 Filed by: Throsby Mark -4.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: